TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02949752
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole 5 mg every morning will be prescribed for 12 weeks
Study: NCT01325428
Drug: Afatinib once daily (OD)
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patient to receive afatinib monotherapy until progression of their disease
Study: NCT01325428
Drug: Vinorelbine Weekly
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients additionally receive vinorelbine weekly on disease progression on afatinib monotherapy
Study: NCT00727207
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03543410
Drug: SEP-4199 200 mg
Normalized name: atropine sulfate / benzoic acid / hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate Oral Tablet [Uri-Sep]
DrugBank: Hyoscyamine (DB00424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEP-4199 200 mg/day (supplied in two 100mg tablets)
Study: NCT03543410
Drug: SEP-4199 400 mg
Normalized name: atropine sulfate / benzoic acid / hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate Oral Tablet [Uri-Sep]
DrugBank: Hyoscyamine (DB00424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEP-4199 400 mg/day (supplied in two 200mg tablets
Study: NCT02902120
Drug: Post-transplant Grazoprevir and Elbasvir
Normalized name: elbasvir and grazoprevir
DrugBank: Elbasvir (DB11574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment will be started in the post-transplant patients on day 0 with the combination pill zepatier, containing grazoprevir 100mg/elbasvir 50mg by mouth once daily. The medications will be continued for a total of 12 weeks (16 weeks if resistance mutations, RAVs, are detected)
Study: NCT04593654
Drug: Dose of tinzaparin or dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will be categorised into three groups depending on initial dose of thromboprophylaxis in the ICU
Study: NCT00022529
Drug: BMS-214662
Normalized name: BMS-214662
DrugBank: BMS-214662 (DB12234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04009044
Drug: Afimoxifene
Normalized name: Afimoxifene
DrugBank: Afimoxifene (DB04468)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply topically
Study: NCT02090400
Drug: Bazedoxifene
Normalized name: Bazedoxifene
DrugBank: Bazedoxifene (DB06401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg Oral daily for 12 months
Study: NCT03730337
Drug: ONO-7475
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-7475 specified dose on specified days
Study: NCT03730337
Drug: ONO-7475 + ONO-4538
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-7475+ONO-4538 specified dose on specified days
Study: NCT01975012
Drug: Rilpivirine
Normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For Cohort 1, Stage 1: RPV will be given orally as a 25-mg film-coated tablet (or for dosing in younger children, as granules \[2.5 mg/g\]) each day with a meal.~For Cohort 1, Stage 2: The dose of RPV will be determined once Cohort 1, Stage 1 data are available.~For Cohort 2: The dose of RPV will be determined once Cohort 1 data are available.
Study: NCT03937583
Drug: Fludeoxyglucose 18F
Normalized name: Fludeoxyglucose (18F)
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The performance of the 18 FDG PET-CT will require fasting of at least 6 hours, and the glycemia will have to be lower than 126 mg / dL before the injection of 3-5 MBq / kg of 18FDG. Intravenous injection will follow a period of approximately 60 minutes in a quiet room.~Computed tomography (CT) will be performed from the middle of the forehead to the feet with normal and shallow breathing using a low dose adjustment Iodinated contrast will not be administered intravenously.
Study: NCT04055792
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab 200mg intravenously on day 1 and Anlotinib 12 mg on days 1-14 once every 3 weeks
Study: NCT02284282
Drug: Spinal injection bupivacaine/morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spinal injection bupivacaine/morphine in laparoscopic surgery
Study: NCT03818581
Drug: Suvorexant
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-mg or 20-mg Suvorexant capsules
Study: NCT02284282
Drug: subcutaneum injection lidocaine
Normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: placebo injection
Study: NCT00533442
Drug: Rapamycin
Normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rapamycin was initiated on day 1 postoperatively, 4mg/day;levels were maintained 5-8ng/ml. Those patients randomized to receive mycophenolate mofetil were given 1gm twice/day starting on the first post-operative day.
Study: NCT00533442
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MMF 1 gm BID beginning 1st day postoperative day
Study: NCT00533442
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part of standard maintenance.
Study: NCT00753467
Drug: IFN-γ 1b (Actimmune)
Normalized name: IFN-gamma 1b
DrugBank: Interferon gamma-1b (DB00033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose
Study: NCT00753467
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil: 1 tablet of 10mg given orally QD
Study: NCT00779376
Drug: Zidovudine 300mg tablets
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01539590
Drug: BB3
Normalized name: LentiGlobin BB305
DrugBank: Betibeglogene autotemcel (DB16900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intravenous administration of 2 mg/kg BB3 for four (4) days
Study: NCT02639585
Drug: Daclinza and Sunvepra
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: direct acting antiviral agent against to hepatitis C virus
Study: NCT00156312
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01414153
Drug: sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered monthly for 4 months
Study: NCT00218257
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200mg progesterone twice daily
Study: NCT04062045
Drug: Ropivacaine Hcl 0.2% Inj Vil 10Ml
Normalized name: ROPIVACAINE HCL 0.2% INJ VIL 10ML
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group A will receive the medicine through the erector spinae catheter.
Study: NCT00332995
Drug: dapivirine (TMC120) vaginal ring
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00295984
Drug: nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01117220
Drug: Ziprasidone Oral Capsules
Normalized name: ziprasidone Oral Capsule
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dose design with minimal dose range of 40 mg twice a day (BID to maximum dose range of 80 mg BID (weight specific- \< 45kg max dose 40 mg BID).
Study: NCT04205266
Drug: Ferumoxytol
Normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV iron infusion
Study: NCT04205266
Drug: Ferrous Sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral iron therapy
Study: NCT03212937
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral KPT-330 is administered on Day 3, 5, and 7 of each 21-day cycle. Starting dose is 40mg will be adjusted according to toxicity
Study: NCT01180660
Drug: Lidocaine Infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 mg/kg bolus followed by an infusion of 2 mg/kg/hr throughout the intra operative period
Study: NCT04354714
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For patients unable to swallow pills, a ruxolitinib suspension will be administered through a nasogastric/orogastric tube
Study: NCT02255422
Drug: Omaveloxolone capsules, 2.5 mg
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02255422
Drug: omaveloxolone capsules, 5 mg
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02255422
Drug: omaveloxolone capsules, 10 mg
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02255422
Drug: omaveloxolone capsules, 20 mg
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02255422
Drug: omaveloxolone capsules, 40 mg
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02255422
Drug: omaveloxolone capsules, 80 mg
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02255422
Drug: omaveloxolone capsules, 160 mg
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02072811
Drug: DAC
Normalized name: DAC
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * DNR 60 mg/m2 0,5h infusion iv on 1-3 days~* 2-CdA 5 mg/m2 2h. infusion iv on 1-5 days~* Ara-C 200 mg/m2 12h infusion iv 2h after end of infusion with 2CdA on 1-7 days
Study: NCT02072811
Drug: CLAG
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * G-CSF 30MU sc, on 0-5 days~* Mitoxantrone 10mg/m2 30 min infusion iv, on 1-3 days~* Cladribine 5mg/m2 in 2h infusion iv, on 1-5 days~* Ara-C 2000mg/m2 4h infusion iv, infusion start after 2h of Cladribine infusion end, on 1-5 day
Study: NCT00834535
Drug: Cefdinir Capsules 300 mg
Normalized name: cefdinir Oral Capsule
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 300 mg, single-dose non-fasting
Study: NCT01343004
Drug: teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: teriparatide 20 mcg subcutaneous daily
Study: NCT03725553
Drug: Intramyometrial Vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a bolus injection of vasopressin (4 IU) diluted to 2 mL with saline into the myometrium of the placental bed during slow (30-seconds) immediately after delivery, as soon as the umbilical cord was clamped.
Study: NCT04408586
Drug: Phentermine-Topiramate Extended Release
Normalized name: phentermine / topiramate
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosing of 3.75/23 mg daily for 15 days, increased to 7.5/46 mg daily
Study: NCT00753467
Drug: IFN-γ 1b and Adefovir dipivoxil combination
Normalized name: IFN-gamma 1b
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose Adefovir dipivoxil: 1 tablet of 10mg given orally QD
Study: NCT01989897
Drug: saline with 1mg/ml Histamine base
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02875080
Drug: OPC-34712
Normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01634594
Drug: Group N
Normalized name: N-6022
DrugBank: N-6022 (DB12206)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03245515
Drug: BMS-986195
Normalized name: BMS-986195
DrugBank: Branebrutinib (DB15347)
Approvals — FDA: no, EMA: no, PMDA: no
Description: specified dose on specified days
Study: NCT02175095
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib will be administered 160 mg/day given orally on day 1 to days 21 following 7 days break, which consists of 4 weeks as 1 cycle. Treatment will be repeated every 4 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
Study: NCT02635750
Drug: BI 409306
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02635750
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03306030
Drug: Split dose of 4L PEG
Normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were given oral instruction for bowel preparation on the day of appointment and re-instruction through phone call on two days before scheduled colonoscopy. They were instructed to have a regular lunch and take only clear liquid or low-residual food for the dinner on the day before colonoscopy. The participants began to drink the first 2 L of PEG at 7:00-9 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
Study: NCT00465621
Drug: Xalatan
Normalized name: Xalatan
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00089011
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00089011
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT00089011
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or PO
Study: NCT00283959
Drug: migalastat HCl
Normalized name: migalastat HCl
DrugBank: Migalastat (DB05018)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02257151
Drug: BMS-986142
Normalized name: BMS-986142
DrugBank: BMS-986142 (DB15291)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01926288
Drug: Entecavir maleate tablets
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01926288
Drug: blank Baraclude tablets
Normalized name: Baraclude
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01926288
Drug: Blank maleate entecavir tablets
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01926288
Drug: Baraclude tablets
Normalized name: Baraclude
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02774837
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil 300mg once daily for 96 weeks
Study: NCT02774837
Drug: Telbivudine
Normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telbivudine oral tablets 600mg once daily for 96 weeks
Study: NCT03502889
Drug: Ropivacaine Hcl 0.5% Inj Vil 30Ml
Normalized name: ROPIVACAINE HCL 0.5% INJ VIL 30ML
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amide local anesthetic, this concentration is commonly used to achieve surgical level anesthesia. The drug itself is not being studied and the same concentration will be used in all participants.
Study: NCT03787758
Drug: SAGE-718
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAGE-718
Study: NCT02570477
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 125mg Vancomycin four times per day
Study: NCT00460733
Drug: Risedronate sodium
Normalized name: Risedronate Sodium
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Actonel® 35 mg (risedronate sodium) and 1000 mg of calcium and 400 UI of Vitamine D3
Study: NCT01874561
Drug: Custirsen
Normalized name: Custirsen
DrugBank: Custirsen (DB05487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Custirsen will be administered iv using an infusion pump over a 2-hour period.
Study: NCT01874561
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg) will be administered orally with 240 mL of room temperature still water.
Study: NCT01420471
Drug: Triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spacer will be impregnated with 2mL of Triamcinolone. The triamcinolone-impregnated spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 days following surgery.
Study: NCT01201161
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal injection of ranibizumab 0.05 ml (0.5 mg) one week before pars plana vitrectomy
Study: NCT00005613
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide will be given at a dose of 600 mg/m2/day over 3.0 hours on days -6, -5, and -4.
Study: NCT00005613
Drug: BCNU
Normalized name: BCNU
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BCNU will be given at a dose of 150 mg/m2/day in 500 cc D5W over 3.0 hours on days -6, -5, and -4
Study: NCT00501787
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00088374
Drug: 17 allylamino-17-demethoxygeldanamycin
Normalized name: 2,4-Bis(allylamino)-6-(4-(bis(p-fluorophenyl)methyl)-1-piperazinyl)-s-triazine
DrugBank: Geldanamycin (DB02424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 allylamino-17-demethoxygeldanamycin (17 AAG) given intravenously at a dose of 300 mg/m2 on days 1,8 and 15 of 28 day cycles.
Study: NCT00088374
Drug: 18 FDG (Fludeoxyglucose 18F)
Normalized name: 18-F FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18FDG PET performed at baseline and 12 weeks after treatment. At each timepoint participants can receive 250mCi 0-15 water and 15 mCi F18-FDG.
Study: NCT00088374
Drug: EPL diluent
Normalized name: DILUENT
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17AAG is formulated with this diluent. Supplied in a 50 mL flint vial containing 48 mL of 2% egg phospholipids, and 5% dextrose in Water for Injection, USP. Patients with a history of serious allergic reactions to eggs should not receive this agent.
Study: NCT04377087
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib is a potent oral poly (ADP-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in BRCA1/2 deficient tumor cells through the formation of double-stranded DNA breaks which cannot be accurately repaired, which leads to disruption of cellular homeostasis and cell death.
Study: NCT03595553
Drug: Ridinilazole
Normalized name: Ridinilazole
DrugBank: Ridinilazole (DB15308)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ridinilazole (200 mg bid)
Study: NCT03595553
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vancomycin (125 mg qid)
Study: NCT01440621
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet Modafinil 100mg (Generic) to be given in 100mg once a day dose, at 8AM daily in the morning, and to be given from Day 1 of Radiation Therapy till the first post treatment follow-up
Study: NCT00661115
Drug: Levitra (Vardenafil, BAY38-9456)
Normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vardenafil 10 mg. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks
Study: NCT03535688
Drug: D-cycloserine
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg twice daily
Study: NCT03537482
Drug: APG-2575
Normalized name: APGA
DrugBank: Aminopterin (DB08878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APG-2575 will be administered as an oral tablet
Study: NCT00428298
Drug: Valacyclovir
Normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects take two 500 mg capsules twice daily for 16 weeks.
Study: NCT01922193
Drug: Highly Purified Urofollitropin
Normalized name: urofollitropin
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: for injection
Study: NCT01922193
Drug: Recombinant Human Follitropin Alfa
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: for injection
Study: NCT02177357
Drug: Pramipexole
Normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01261728
Drug: Gemcitabine and Cisplatin
Normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive four cycles of GC administered every 21 days. Gemcitabine 1,000 mg/m2 and Cisplatin 35 mg/m2 will be administered intravenously on days 1 and 8. A total of four cycles of therapy will be administered at 21 day intervals followed by radical nephroureterectomy or distal ureterectomy.
Study: NCT03155425
Drug: SHR-1210
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A humanized monoclonal immunoglobulin
Study: NCT01696825
Drug: Diazepam tablet, 5 mg, vaginal
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam tablet, 5 mg, moistened and inserted vaginally
Study: NCT01696825
Drug: Diazepam Suppository, 5 mg, vaginal
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compounded diazepam 5 mg suppository administered vaginally
Study: NCT01696825
Drug: Diazepam Cream, 5 mg, Vaginal
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compounded diazepam cream, 5 mg, inserted vaginally
Study: NCT01594983
Drug: Fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate once daily 12 weeks